Ashkan Shoamanesh: FDA Grants Asundexian A Priority Review for Secondary Stroke Prevention
Ashkan Shoamanesh, Associate Professor of Medicine (Neurology), Marta and Owen Boris Chair in Stroke Research and Care at McMaster University, shared on LinkedIn:
”Excellent news for patients with ischemic stroke and high-risk TIA: the U.S. FDA has granted Priority Review to asundexian for secondary stroke prevention based on the results of the OCEANIC-STROKE trial.
This marks an important step toward the potential rapid availability of a novel treatment strategy aimed at reducing recurrent ischemic events without increasing major bleeding risk – a long-standing unmet need in stroke prevention.
Very hopeful that other global regulatory agencies will follow suit so that patients worldwide may benefit from timely access to this therapy.”
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 21, 2026, 15:26Mariusz Kruk: Plaque-Directed Intervention for the Prevention of Myocardial Infarction
-
Aug 21, 2026, 15:17Leveraging Data to Drive Sustainable Care for Haemophilia and Haemoglobinopathies – NNHF
-
Aug 21, 2026, 15:04Sex Differences in Platelet Function in Type 2 Diabetes – Seminars in Thrombosis and Hemostasis
-
Aug 21, 2026, 15:04Parth Parmar: RBC Morphology – A Practical Guide to Blood Smear Interpretation
-
Aug 21, 2026, 14:32Kenneth Nollet: Building the Future of Transfusion Laboratory Science
-
Aug 21, 2026, 14:14Tareq Abadl: A Positive Antibody Screen is Not The Diagnosis
-
Aug 21, 2026, 14:08Katrina Snow։ Transfusion Trends and Quality Improvement in Sickle Cell Disease
-
Aug 21, 2026, 14:00Rucha Patil: The Power of Point-of-Care Testing in Hemostasis
-
Aug 21, 2026, 13:56Sarah Kowalski։ Supporting the Next Generation of Transfusion Laboratory Scientists